Venture Partners Vi Lpovp V... Net Worth

The estimated Net Worth of Venture Partners Vi Lpovp V... is at least $6.16 Milion dollars as of 2 September 2014. Venture V owns over 35,000 units of Nanostring Technologies Inc stock worth over $177,331 and over the last 11 years Venture sold NSTG stock worth over $5,981,793.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture V NSTG stock SEC Form 4 insiders trading

Venture has made over 5 trades of the Nanostring Technologies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture sold 35,000 units of NSTG stock worth $390,250 on 2 September 2014.

The largest trade Venture's ever made was selling 166,755 units of Nanostring Technologies Inc stock on 11 June 2014 worth over $2,514,665. On average, Venture trades about 51,352 units every 11 days since 2013. As of 2 September 2014 Venture still owns at least 1,684,054 units of Nanostring Technologies Inc stock.

You can see the complete history of Venture V stock trades at the bottom of the page.

Insiders trading at Nanostring Technologies Inc

Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus... a Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.

What does Nanostring Technologies Inc do?

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali

Complete history of Venture V stock trades at Nanostring Technologies Inc

Nanostring Technologies Inc executives and stock owners

Nanostring Technologies Inc executives and other stock owners filed with the SEC include:

• R. Bradley Gray,
  President, Chief Executive Officer, Director
• K. Thomas Bailey,
  Chief Financial Officer
• Joseph Beechem,
  Senior Vice President - Research and Development
• John Brown,
  Senior Vice President - Sales and Marketing
• David Ghesquiere,
  Senior Vice President - Corporate and Business Development
• R. Bradley Gray,
  CEO, Pres & Director
• K. Thomas Bailey M.B.A.,
  Chief Financial Officer
• Dr. Joseph M. Beechem,
  Chief Scientific Officer and Sr. VP of R&D
• J. Chad Brown,
  Sr. VP of Sales & Marketing
• David W. Ghesquiere,
  Sr. VP of Corp. & Bus. Devel.
• William Young,
  Independent Chairman of the Board
• Gregory Norden,
  Independent Director
• Don Kania,
  Independent Director
• Charles Waite,
  Independent Director
• Elisha Finney,
  Independent Director
• Kirk Malloy,
  Independent Director
• Robert Hershberg,
  Independent Director
• Elizabeth Schneider Ph.D.,
  Sr. Global Marketing Mang.
• Dr. Philippa Webster Ph.D.,
  Sr. Principal Scientist
• Dr. Mary Tedd Allen,
  Sr. VP of Strategic Initiatives
• Kathryn Surace-Smith,
  Sr. VP of HR & Legal Affairs and Corp. Sec.
• Douglas S. Farrell,
  VP of Investor Relations & Corp. Communications
• Mark A. Winham,
  Sr. VP of Operations
• Teresa M. Foy,
  Director
• Nicholas Galakatos,
  Director
• Lifesciences Ii, L.P.Clarus...,
  
• Wayne Burns,
  SVP, Operations & Admin
• James A Johnson,
  Chief Financial Officer
• J. Chad Brown,
  SVP, Sales & Marketing
• Mary Tedd Allen,
  SVP, Operations
• Lifesciences Ii, L.P.Clarus...,
  
• Barney Saunders,
  SVP & GM, Life Sciences
• Venture Partners Vi Lpovp V...,
  
• Fisher Jurvetson Fund Vii, ...,
  
• Finny Kuruvilla,
  Director
• Tina Susan Nova,
  Director
• Bruce J. Seeley,
  SVP & GM, Diagnostics
• J Wayne Cowens,
  Chief Medical Officer
• Jennifer Scott Fonstad,
  Director
• Bradford Crutchfield,
  Director
• Janet George,
  Director
• Dana E. Rollison,
  Director
• John D. Gerace,
  Chief Commercial Officer
• Jonathan Todd Garland,
  Chief Commercial Officer